These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 30171544)
1. Skipping of Duplicated Dystrophin Exons: In Vitro Induction and Assessment. Greer K; Fletcher S; Wilton SD Methods Mol Biol; 2018; 1828():219-228. PubMed ID: 30171544 [TBL] [Abstract][Full Text] [Related]
2. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy. Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397 [TBL] [Abstract][Full Text] [Related]
3. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression. Lee JJA; Saito T; Duddy W; Takeda S; Yokota T Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539 [TBL] [Abstract][Full Text] [Related]
4. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998 [TBL] [Abstract][Full Text] [Related]
5. Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide Approach. Wein N; Vulin A; Findlay AR; Gumienny F; Huang N; Wilton SD; Flanigan KM J Neuromuscul Dis; 2017; 4(3):199-207. PubMed ID: 28869484 [TBL] [Abstract][Full Text] [Related]
16. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910 [TBL] [Abstract][Full Text] [Related]
17. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle. Popplewell LJ; Graham IR; Malerba A; Dickson G Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027 [TBL] [Abstract][Full Text] [Related]
18. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800 [TBL] [Abstract][Full Text] [Related]
19. Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies. Toh ZY; Thandar Aung-Htut M; Pinniger G; Adams AM; Krishnaswarmy S; Wong BL; Fletcher S; Wilton SD PLoS One; 2016; 11(1):e0145620. PubMed ID: 26745801 [TBL] [Abstract][Full Text] [Related]